MX2016002372A - Beta-caseina a2 y niveles de glucosa en sangre. - Google Patents

Beta-caseina a2 y niveles de glucosa en sangre.

Info

Publication number
MX2016002372A
MX2016002372A MX2016002372A MX2016002372A MX2016002372A MX 2016002372 A MX2016002372 A MX 2016002372A MX 2016002372 A MX2016002372 A MX 2016002372A MX 2016002372 A MX2016002372 A MX 2016002372A MX 2016002372 A MX2016002372 A MX 2016002372A
Authority
MX
Mexico
Prior art keywords
casein
beta
blood glucose
glucose levels
animal
Prior art date
Application number
MX2016002372A
Other languages
English (en)
Inventor
John Clarke Andrew
Original Assignee
A2 Milk Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52483940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016002372(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by A2 Milk Co Ltd filed Critical A2 Milk Co Ltd
Publication of MX2016002372A publication Critical patent/MX2016002372A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
    • A23J1/202—Casein or caseinates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332—Promoters of weight control and weight loss
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/54—Proteins
    • A23V2250/542—Animal Protein
    • A23V2250/5424—Dairy protein
    • A23V2250/54246—Casein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Animal Husbandry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pediatric Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

Regular el nivel de glucosa en la sangre de un animal que comprende el consumo por el animal de una composición que contiene beta-caseína, o proporcionar la composición al animal para consumo, donde la beta-caseína comprende al menos 75% en peso de beta-caseína A2. Los usos incluyen manejar los síntomas de hiperglicemia y condiciones asociadas que incluyen diabetes. El efecto es tanto agudo (post-exposición a la composición) como continuo.
MX2016002372A 2013-08-23 2014-08-22 Beta-caseina a2 y niveles de glucosa en sangre. MX2016002372A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361869213P 2013-08-23 2013-08-23
PCT/NZ2014/000172 WO2015026245A1 (en) 2013-08-23 2014-08-22 Beta-casein a2 and blood glucose levels

Publications (1)

Publication Number Publication Date
MX2016002372A true MX2016002372A (es) 2016-12-20

Family

ID=52483940

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016002372A MX2016002372A (es) 2013-08-23 2014-08-22 Beta-caseina a2 y niveles de glucosa en sangre.
MX2020006720A MX2020006720A (es) 2013-08-23 2016-02-23 Beta-caseina a2 y niveles de glucosa en sangre.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020006720A MX2020006720A (es) 2013-08-23 2016-02-23 Beta-caseina a2 y niveles de glucosa en sangre.

Country Status (18)

Country Link
US (2) US10568933B2 (es)
EP (2) EP3943100A1 (es)
JP (2) JP6866159B2 (es)
KR (2) KR102626825B1 (es)
CN (1) CN105555295A (es)
AU (2) AU2014309522B2 (es)
CA (2) CA3235298A1 (es)
ES (1) ES2899732T3 (es)
HK (1) HK1225618A1 (es)
IL (2) IL243845B (es)
MX (2) MX2016002372A (es)
MY (1) MY192873A (es)
NZ (1) NZ717171A (es)
PH (1) PH12016500213B1 (es)
RU (1) RU2698794C2 (es)
SG (2) SG11201600670VA (es)
WO (1) WO2015026245A1 (es)
ZA (1) ZA201600816B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10568933B2 (en) 2013-08-23 2020-02-25 The A2 Milk Company Limited Beta-casein A2 and blood glucose levels
EP4194001A1 (en) * 2015-04-22 2023-06-14 Cedars-Sinai Medical Center Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes and obesity
WO2016190750A1 (en) * 2015-05-22 2016-12-01 The A2 Milk Company Limited Beta-casein a2 and antioxidant capacity
WO2017003300A1 (en) * 2015-06-29 2017-01-05 The A2 Milk Company Limited A2 beta-casein and viscosity of milk products
WO2017111618A1 (en) * 2015-12-22 2017-06-29 The A2 Milk Company Limited Infant formula comprising human milk peptides
JP2017165661A (ja) * 2016-03-14 2017-09-21 雪印メグミルク株式会社 糖質代謝改善剤
JP7394527B2 (ja) 2016-03-30 2023-12-08 ズィ・エイツー・ミルク・カンパニー・リミテッド ベータカゼイン類および認知機能
US11925197B2 (en) 2016-09-30 2024-03-12 The A2 Milk Company Limited Beta-caseins and gut microbiota

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69536000D1 (de) * 1994-11-04 2009-10-22 A2 Corp Ltd Selektionsverfahren für nicht-diabetogene milch oder milchprodukte sowie hierdurch erfasste milch oder milchprodukte
US7094949B2 (en) * 1995-05-16 2006-08-22 A2 Corporation Limited Breeding and milking cows for milk free of β-casein A1
CA2217820C (en) 1995-05-16 2011-03-01 Corran Norman Stuart Mclachlan Milk and milk products for preventing or treating heart disease
EP1196047A4 (en) * 1999-06-29 2004-12-22 New Zealand Milk Inst Ltd MILK-BASED PROPHYLACTIC FOOD SUPPLEMENTS
AU9037401A (en) 2000-09-08 2002-03-22 New Zealand Dairy Board Milk containing beta-casein with proline at position 67 does not aggravate neurological disorders
JP2005531325A (ja) * 2002-07-03 2005-10-20 エイツー・コーポレーション・リミテッド 生乳の脂肪酸の組成を変える方法
US20060280802A1 (en) * 2002-10-04 2006-12-14 Campbell Julie H Therapeutic uses of beta-casein a2 and dietary supplement containing beta-casein a2
RU2402243C2 (ru) * 2004-07-19 2010-10-27 Н.В. Нютрисиа Препарат для применения аспартата для регулирования уровней глюкозы в крови
EP2745709A1 (en) * 2012-12-24 2014-06-25 Abbott Laboratories, Inc. Nutritional compositions with reduced beta-casein a1 and related methods
US10568933B2 (en) 2013-08-23 2020-02-25 The A2 Milk Company Limited Beta-casein A2 and blood glucose levels

Also Published As

Publication number Publication date
AU2019204101A1 (en) 2019-07-04
EP3035951A1 (en) 2016-06-29
RU2016103489A (ru) 2017-09-28
IL243845B (en) 2018-02-28
SG11201600670VA (en) 2016-02-26
JP6866159B2 (ja) 2021-04-28
KR102626825B1 (ko) 2024-01-17
MY192873A (en) 2022-09-13
HK1225618A1 (zh) 2017-09-15
JP2019011342A (ja) 2019-01-24
ZA201600816B (en) 2017-11-29
PH12016500213A1 (en) 2016-04-25
US20200129590A1 (en) 2020-04-30
ES2899732T3 (es) 2022-03-14
IL257228A (en) 2018-03-29
MX2020006720A (es) 2020-08-20
KR102270059B1 (ko) 2021-06-28
SG10201801156RA (en) 2018-03-28
AU2019204101B2 (en) 2021-09-02
JP7082551B2 (ja) 2022-06-08
JP2016532702A (ja) 2016-10-20
AU2014309522B2 (en) 2019-11-07
KR20210022776A (ko) 2021-03-03
CA3235298A1 (en) 2015-02-26
RU2016103489A3 (es) 2018-06-18
IL243845A0 (en) 2016-04-21
EP3035951A4 (en) 2017-04-19
AU2014309522A1 (en) 2016-03-10
WO2015026245A1 (en) 2015-02-26
PH12016500213B1 (en) 2016-04-25
US10568933B2 (en) 2020-02-25
KR20160044580A (ko) 2016-04-25
US20160324922A1 (en) 2016-11-10
EP3035951B1 (en) 2021-09-15
RU2698794C2 (ru) 2019-08-30
CN105555295A (zh) 2016-05-04
NZ717171A (en) 2022-05-27
EP3943100A1 (en) 2022-01-26
IL257228B (en) 2020-02-27
CA2920152A1 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
MX2020006720A (es) Beta-caseina a2 y niveles de glucosa en sangre.
MX2015008011A (es) Suplementos y sistemas de monitoreo para la dosificacion de los suplementos.
EA201101189A1 (ru) Ингибитор sglt-2, предназначенный для лечения сахарного диабета типа 1, сахарного диабета типа 2, нарушенной толерантности к глюкозе или гипергликемии
PH12016500905A1 (en) Nutritional compositions with phospholipids
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
PH12015502674B1 (en) Beta-casein a2 and prevention of inflammation of the bowel
BR112013003160A2 (pt) tratamento de diabetes com células precursoras endócrinas pancráticas
BR112015024354A2 (pt) método de determinação do sexo de um embrião em um ovo
NZ754642A (en) Beta-casein a2 and reducing or preventing symptoms of lactose intolerance
MX366527B (es) Composiciones nutricionales que contienen treonato de magnesio y usos de las mismas.
MX2016007715A (es) Composicion nutricional para reducir el estres metabolico en infantes.
MX2015003642A (es) Cmpf como biomarcador para diabetes y metodos asociados.
BR112013011259A2 (pt) condições de tratamento associadas com nível aumentado de eotaxina com 25-hidroxivitamina d3
WO2011031335A3 (en) System utilizing physiological monitoring and electronic media for health improvement
PH12017500017A1 (en) A combination of vitamin d and zinc and its use
NZ759287A (en) Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose
BR112012031053A2 (pt) uso de 2-aminoetanol, e, método para aumentar o ph de uma suspensão aquosa.
PH12017500084A1 (en) Vitamin b2 and its use
WO2008085921A3 (en) Methods for reduction of adipose tissue mass
TH177298A (th) เบต้า-เคซีน a2 และระดับกลูโคสในเลือด
WO2015173769A3 (en) System and methods for sensory controlled satisfaction monitoring
ES2538601A1 (es) Composición alimenticia de miel
Strandberg Low carbohydrate diets increase saturated fat consumption
MX2015012821A (es) Tratamiento de resistencia a la insulina asociado con la inactividad fisica prolongada.
Vazin Afzal Fath-Ali Shah's Politics in Qom and Fatemeh Ma'sumeh's shrine development

Legal Events

Date Code Title Description
FG Grant or registration